Yellow fever virus is found in tropical and subtropical, and caused an estimated 29,000 to 60,000 deaths in 2013. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus. The Phase 1 study is evaluating whether an experimental vaccine developed by the Danish biopharmaceutical company Bavarian Nordic is safe, tolerable and has the potential to prevent yellow fever virus infection.
Related posts:
- Medicare Card, Large-scale HIV vaccine trial to launch in South Africa Medicare Card, Large-scale HIV vaccine trial to launch in South Africa...
- Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial...
- Medicare Card, NIH launches trial of investigational genital herpes vaccine Medicare Card, NIH launches trial of investigational genital herpes vaccine...
- Medicare Card: NIH-Supported Experimental Marburg Vaccine Prevents Disease Two Days after Infection An experimental vaccine developed to prevent outbreaks of Marburg hemorrhagic fever continues to show promise in monkeys as an emergency treatment for accidental exposures to the virus that causes the disease. There is no licensed treatment for Marburg infection, which has a high fatality rate....
- Medicare Card, NIH begins testing investigational Zika vaccine in humans Medicare Card, NIH begins testing investigational Zika vaccine in humans...
- Medicare Card, Investigational malaria vaccine protects healthy U.S. adults for more than one year Medicare Card, Investigational malaria vaccine protects healthy U.S. adults for more than one year...
- Chikungunya vaccine trial begins to enroll participants An experimental vaccine to prevent chikungunya fever, a viral disease spread by certain species of mosquitoes, is being tested in a clinical trial conducted by National Institute of Allergy and Infectious Diseases (NIAID) scientists at the National Institutes of Health....
- Medicare Card,NIH scientists develop candidate vaccine against respiratory syncytial virus An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science....
- Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins...
- Medicare Card, NIH launches human RSV study Medicare Card, NIH launches human RSV study...
- Possible clues found to why HIV vaccine showed modest protection Insights into how the first vaccine ever reported to modestly prevent HIV infection in people might have worked were published online today in the New England Journal of Medicine. Scientists have found that among adults who received the experimental HIV vaccine during the landmark RV144 clinical trial, those who produced relatively high levels of a […]...
- Medicare Card, NIH study finds factors that may influence influenza vaccine effectiveness Medicare Card, NIH study finds factors that may influence influenza vaccine effectiveness...
- Medicare Card, New NIH-funded memory drug moves into Phase 1 clinical study Medicare Card, New NIH-funded memory drug moves into Phase 1 clinical study...
- Researchers identify cause and new treatment for common recurrent fever in children A preliminary study conducted by a team at the National Institutes of Health has identified a promising new treatment in children for the most common periodic fever disease in children. The syndrome is called periodic fever associated with aphthous stomatitis, pharyngitis and cervical adenitis — or PFAPA — and is characterized by monthly flare-ups of […]...
- Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease...